中
Home
About TUL
Group Introduction
Executive Directors
Subsidiaries
Contact Us
Innovation in R&D
R&D Pipeline
R&D Platform
R&D Updates
News
TUL Highlights
Product Center
Finished Products
Comprehensive Health Products
APIs and Intermediates
Animal protection products
Empty capsule
Medical device
Cosmetic Peptide Series
Sustainability
Enhancing Governance
Normalizing Healthiness
Brand Building
People-Oriented
Green Development
ESG Reports
ESG News
Investor Relations
News
TUL Highlights
2026-07-15
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT SODIUM HYALURONATE EYE DROPS WITH NEW SPECIFICATION
Learn More
2026-07-03
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT TADALAFIL TABLETS
Learn More
2026-06-22
Tsoi Hoi Shan Attended Novo Nordisk Roundtable to Discuss the Global Impact of Chinese Innovation
Learn More
2026-06-12
APPROVAL FOR CLINICAL TRIAL OF THE GROUP’S PRODUCT TUL321 CAPSULES
Learn More
2026-05-20
APPROVAL FOR CLINICAL TRIAL OF GROUP’S PRODUCT TUL108 FOR INJECTION
Learn More
All News
Select Year
2026
2025
2024
First batch in Guangdong! Three varieties including TUL’s liraglutide injection were approved as pilot products for segmented production
2025-01-02
TUL Makes Its Debut at CPHI Middle East
2024-12-13
TUL Receives the Title of “Most Valuable Pharmaceutical and Medical Company”
2024-12-12
TUL’s Mupirocin Ointment Receives Marketing Approval
2024-12-12
Zhuhai United Laboratories Co., Ltd. Passes Online GMP Inspection by Mexican Authorities
2024-12-12
TUL’s Sterile Amoxicillin Sodium Bulk Medicine Obtains CEP Certificate
2024-12-02
A new milestone in power supply! The United Laboratories (Inner Mongolia) Co., Ltd. held the commissioning ceremony for its 110KV substation
2024-12-02
TUL Participates in Pharmtech & Ingredients 2024 in Russia
2024-11-22
The United Laboratories (Inner Mongolia) Co., Ltd. Completes On-Site South Korean GMP Inspection
2024-11-21
Prev
1
...
10
11
12
13
14
...
17
Next
WeChat
Official
Account
To Top
粤公网安备44040402000348号
